S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Stock market today: Asian shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
BREAKING: Tiny biotech successfully treats blindness (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Stock market today: Asian shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
BREAKING: Tiny biotech successfully treats blindness (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Stock market today: Asian shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
BREAKING: Tiny biotech successfully treats blindness (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Stock market today: Asian shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
BREAKING: Tiny biotech successfully treats blindness (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
OTCMKTS:PPCB

Propanc Biopharma (PPCB) Stock Forecast, Price & News

$0.03
0.00 (0.00%)
(As of 09/20/2023 ET)
Compare
Today's Range
$0.02
$0.03
50-Day Range
$0.03
$0.12
52-Week Range
$0.02
$0.26
Volume
147,557 shs
Average Volume
465,356 shs
Market Capitalization
$88,447.20
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

PPCB stock logo

About Propanc Biopharma (OTCMKTS:PPCB) Stock

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

PPCB Price History

PPCB Stock News Headlines

This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
PPCB - Propanc Biopharma, Inc.
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Propanc Biopharma Announces Reverse Stock Split
PPCB Propanc Biopharma, Inc.
See More Headlines
Receive PPCB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Propanc Biopharma and its competitors with MarketBeat's FREE daily newsletter.

PPCB Company Calendar

Today
9/21/2023
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PPCB
Employees
1
Year Founded
N/A

Profitability

Net Income
$-2,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($13.75) per share

Miscellaneous

Free Float
3,229,000
Market Cap
$88,447.20
Optionable
Not Optionable
Beta
1.59
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. James Nathanielsz (Age 49)
    Exec. Chairman, CEO, CFO, Treasurer & Sec.
    Comp: $349.38k
  • Dr. Julian Norman Kenyon ChB (Age 75)
    M.D., MB, Chief Scientific Officer, CTO & Director
    Comp: $35.99k
  • Prof. Klaus Kutz
    Chief Medical Officer & Member of Scientific Advisory Board













PPCB Stock - Frequently Asked Questions

How have PPCB shares performed in 2023?

Propanc Biopharma's stock was trading at $0.60 at the beginning of 2023. Since then, PPCB shares have decreased by 95.5% and is now trading at $0.0269.
View the best growth stocks for 2023 here
.

When did Propanc Biopharma's stock split?

Propanc Biopharma shares reverse split before market open on Tuesday, May 23rd 2023. The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

What other stocks do shareholders of Propanc Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Propanc Biopharma investors own include Avis Budget Group (CAR), Cronos Group (CRON), CRISPR Therapeutics (CRSP), Petroteq Energy (PQEFF), Xerox (XRX), Aurora Cannabis (ACBFF), Amgen (AMGN), Amarin (AMRN) and Aphria (APHQF).

What is Propanc Biopharma's stock symbol?

Propanc Biopharma trades on the OTCMKTS under the ticker symbol "PPCB."

How do I buy shares of Propanc Biopharma?

Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Propanc Biopharma's stock price today?

One share of PPCB stock can currently be purchased for approximately $0.03.

How much money does Propanc Biopharma make?

Propanc Biopharma (OTCMKTS:PPCB) has a market capitalization of $88,447.20.

How can I contact Propanc Biopharma?

Propanc Biopharma's mailing address is 302/6 BUTLER STREET VICTORIA, CAMBERWELL C3, 3124. The official website for the company is www.propanc.com. The company can be reached via phone at (139) 882-0780, via email at irteam@propanc.com, or via fax at 61 03 9882 9969.

This page (OTCMKTS:PPCB) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -